(603309)"Well Lead Medical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603309 · · 11 pages · Chinese
Summary by 6ix AI
The report indicates a slight increase in revenue compared to the previous year, but a significant decline in net profit attributable to shareholders. The company attributes the profit decrease to the impact of national procurement policies and increased financial costs due to currency fluctuations. Total assets have decreased slightly, while equity attributable to shareholders has increased compared to the end of the previous year.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Well Lead Medical Co Ltd on 6ix
Earlier from Well Lead Medical
- (603309)"Well Lead Medical Co., Ltd."Announcement on the Company's Products Obtaining EU MDR Certification
- (603309)"Well Lead Medical Co., Ltd."Announcement on Extension of Pledge and Supplementary Pledge of Shares Held by Shareholder
- (603309)"Well Lead Medical Co., Ltd."Announcement on Change of Contact Information for Investors
- Announcement on Supplemental Pledge of Shares Held by Shareholder
- Announcement on Resolutions of the 1st Meeting of the 6th Board of Directors
Later from Well Lead Medical
- (603309)"Well Lead Medical Co., Ltd."Announcement on Obtaining Class II Medical Device Registration Certificate for the Company's Product
- (603309)"Well Lead Medical Co., Ltd."Announcement on Implementation of Dividend Distribution for Q3 2026
Follow Well Lead Medical into a list and get an email when it puts out news.
Follow Well Lead Medical